Gainers PDS Biotechnology (NASDAQ:PDSB) shares rose 63.7% to $0.65 during Tuesday's regular ses

FDA clearance of a new IND for GTB-5550 in multiple myeloma (MM) under an investigator sponsored tri

FDA clearance of a new IND for GTB-5550 in multiple myeloma (MM) under an investigator sponsored tri

FDA clearance of a new IND for GTB-5550 in multiple myeloma (MM) under an investigator sponsored tri

GT Biopharma secures FDA IND clearance for GTB-5550, advancing its TriKE therapy into Phase 1 clinic

Gainers Basel Medical Group (NASDAQ:BMGL) shares moved upwards by 59.8% to $7.32 during Monday'

GT Biopharma, Inc. (GTBP) Discusses TriKE Platform, Clinical Progress, and the Case for NK Cell Immu

Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) shares increased by 110.6% to $1.39 during Friday&#39

SAN FRANCISCO, CALIFORNIA, Sept. 11, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NA

Gainers iSpecimen (NASDAQ:ISPC) shares increased by 10.4% to $1.7 during Friday's after-market

GT Biopharma (NASDAQ:GTBP) reported quarterly losses of $(0.12) per share which missed the analyst c

Phase 1 trial evaluating GTB-3650 TriKE ® remains ongoing, with an update anticipated in 2H 2026

Issued on behalf of GT Biopharma, Inc. (Nasdaq: GTBP) A clinical-stage immuno-oncology company has m

Increased integration of artificial intelligence–based tools across the discovery and engineering of

GT Biopharma says AI-driven drug discovery tools are accelerating pipeline development and may yield

/PRNewswire/ -- USA News Group Market Commentary - Start with the number that makes everyone do a do

https://www.sec.gov/ix?doc=/Archives/edgar/data/109657/000149315226024913/form8-k.htm

/PRNewswire/ -- USA News Group News Commentary - For more than two decades, B7-H3 sat on the shortli

GT Biopharma (NASDAQ:GTBP) reported quarterly losses of $(0.11) per share which missed the analyst c

Phase 1 trial evaluating GTB-3650 TriKE ® remains ongoing, with additional updates anticipated in 2H

GTB-5550 is now the 3rd TriKE ® to enter the clinic and an expansion into a broader solid tumor oppo

GT Biopharma Inc. (NASDAQ:GTBP) on Thursday dosed the first patient on a Phase 1 dose-escalation bas

GT Biopharma doses first patient in Phase 1 GTB-5550 trial targeting B7-H3-positive solid tumors wit

Cogent Biosciences (NASDAQ: COGT - Get Free Report) and GT Biopharma (NASDAQ: GTBP - Get Free Report

GT Biopharma (GTBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about th

GT Biopharma (GTBP) witnesses a hammer chart pattern, indicating support found by the stock after lo

SAN FRANCISCO, CALIFORNIA, March 11, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NA

GT Biopharma (NASDAQ:GTBP) reported quarterly losses of $(4.84) per share. This is a 191.57 percent

Year Ended December 31, 2025 Financial SummaryCash Position: The Company had cash and cash equivalen

Phase 1 trial evaluating GTB-3650 TriKE ® continues to actively enroll, with the next update anticip

SAN FRANCISCO, CALIFORNIA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NAS

GTB-5550 Phase 1 dose escalation basket trial expected to initiate mid-2026Phase 1 protocol allows m

GTB-5550 Phase 1 dose escalation basket trial expected to initiate mid-2026 Phase 1 protocol allows

GT Biopharma targets a portion of the estimated $362 billion global solid tumor market Preliminary,

GT Biopharma Inc. (NASDAQ: GTBP) on Thursday said it submitted an investigational new drug (IND) app

GT Biopharma submitted an IND application for GTB-5550 TriKE for solid tumors. Phase 1 trial planned

GT Biopharma targets a portion of the estimated $362 billion global solid tumor market with its B7-H

 Within this landscape, GT Biopharma (NASDAQ:GTBP) is advancing a proprietary platform designed to h